Biohaven Ltd. (BHVN) · Oct 29, 2026 · Earnings

Biohaven earnings miss as $480M licensing cash reshapes runway

Miss — Adjusted EPS $(0.73) vs ~$0.61 consensus

Biohaven’s third-quarter earnings missed the published EPS benchmark, while Ono and SK licensing deals materially strengthen funding for its clinical pipeline.

Biohaven is a clinical-stage biotech building MoDE and TRAP extracellular protein-degrader platforms, with BHV-1300 already in Phase 3 for Graves’ disease and BHV-1400 moving toward pivotal testing in IgA nephropathy. Its other major value driver, opakalim, remains in epilepsy development but is currently subject to a partial FDA hold on new enrollment.

The quarter itself missed the clean earnings benchmark. Adjusted loss per share was $0.73 versus a published consensus of roughly $0.61, while GAAP loss per share was $0.86. The year-over-year improvement came mainly from lower R&D spending after the company reprioritized programs, not from commercial revenue or a nearer-term product launch. The company reported adjusted net loss of $110.7 million versus $155.9 million a year earlier.

Q3 2026Q3 2025Consensus
GAAP net loss/share (Income Statement)$(0.86)$(1.64)
Adjusted net loss/share (Non-GAAP reconciliation)$(0.73)$(1.47)$(0.61)
R&D expense ($M) (R&D Expenses)$101.9$141.2
Cash, cash equivalents, marketable securities and restricted cash ($M) (Liquidity)$164.0

The bigger change is financial rather than quarterly. The Ono agreement has already delivered $80 million, with another $20 million milestone payment possible within roughly a year, while the SK Biopharmaceuticals deal is expected to provide $350 million at closing and another $50 million one year later. Together, those agreements represent up to $480 million of near-term cash consideration, although the SK proceeds remain dependent on closing.

The deals validate the platforms but also expose the remaining execution risk. Ono is taking regional rights to the MoDE IgG portfolio while Biohaven retains major territories, and SKBP is taking worldwide rights to the Kv7 platform. That gives Biohaven outside funding and development partners for two strategic assets, but the most valuable epilepsy program is not fully de-risked: the FDA has paused new opakalim enrollment while Biohaven completes additional nonclinical metabolite studies. 〔0〕

Regulatory optionality remains a meaningful near-term catalyst. The FDA accepted Biohaven’s Vyglxia resubmission for review, deemed it a complete response to the prior action letter, and assigned a user-fee goal date in the first quarter of 2027. That is new progress, but the planned advisory-committee review means approval is still a decision point rather than an achieved milestone. 〔1〕

Bottom line: This was an earnings miss, but the business story improved more than the quarter’s loss suggests because licensing proceeds can fund the pipeline without immediate equity dilution. The read is mixed because the central epilepsy asset still carries a regulatory hold and the largest SK payment has not yet closed.

What to watch next

RISE 3 topline data, 2H 2026

Original filing on SEC EDGAR

More Biohaven Ltd. news

Biohaven earnings miss as $480M licensing cash reshapes runway | BHVN Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.